1,721,571 research outputs found
Comments on the article "Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations" by Marfella et al.: (Journal of Diabetes and Its Complications 24 [2010] 79-83)
No full text
Contribution of 3-hydroxyisobutyrate to the measurement of 3-hydroxybutyrate in human plasma: comparison of enzymatic and gas-liquid chromatography-mass spectrometry assays in normal and in diabetic subjects.
No full textAbnormalities of the cardiac stem and progenitor cell compartment in experimental and human diabetes.
No full text
Microvascular complications in diabetes: A growing concern for cardiologists
No full textRandomized, cross-sectional, and prospective studies have demonstrated that microvascular complications in patients with diabetes are not only the cause of blindness, renal failure and non-traumatic amputations, but also powerful predictors of cardiovascular complications. Beside the metabolic theory, the pathophysiology of diabetic microvascular complications is determined by the interaction among several factors, including epigenetic modifications and the reduced release of progenitor cells by the bone marrow, that contribute simultaneously to damage and impaired vascular protection against hyperglycemia. Identifying and preventing microvascular complications has the significant potential to reduce major adverse cardiovascular events. For these reasons, there may no longer be a rational to consider microangiopathy and macroangiopathy as entirely separate entities, but they should most likely be viewed as a continuum of the widespread vascular damage determined by diabetes mellitus
Endothelial progenitor cells in diabetes mellitus and its complications [Le cellule progenitrici endoteliali el diabete mellito sue complicanze]
No full textEndothelial progenitor cells (EPCs) are bone marrow-derived stem cells involved in endothelial repair and neo-angiogenesis. Quantitative and qualitative EPC alterations associate with classical cardiovascular risk factors as well as with established atherosclerotic diseases. Type 1 and type 2 diabetic patients show reduction and dysfunction of circulating EPCs, when compared to non diabetic subjects. In the presence of micro- and macrovascular diabetic complications, EPC levels are further reduced in parallel with disease severity. The causes of low EPCs in diabetes are not entirely clear, but defects in bone marrow mobilization processes appear to be predominantly involved. Low EPCs levels predict incident cardiovascular events in different cohorts of patients. Some pharmacological interventions are able to restore circulating EPCs levels, but it remains to be established whether or not this translates into cardiovascular protectio
- …
